On October 29, 2026, Annovis Bio, Inc. received a notice from the New York Stock Exchange (NYSE) indicating that it is no longer compliant with the exchange's continued listing standards. This notice comes as the company’s average market capitalization fell below $50 million, while its stockholders' equity also reported a deficit.

The implications of this notification are significant for Annovis Bio, a clinical-stage biotechnology company focused on developing treatments for neurodegenerative diseases such as Alzheimer's and Parkinson's. The company must now act swiftly to submit a plan to the NYSE detailing how it intends to regain compliance within nine months.

Background

Annovis Bio, Inc. operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. The company is publicly traded on the NYSE under the ticker symbol ANVS. Recently, Annovis has been navigating challenges typical of smaller reporting companies, particularly in the volatile biotech sector.

What the Filing Says

According to the SEC filing (accession number 0001104659-26-120732), the NYSE's notice outlined that as of October 28, 2026, Annovis’ average market capitalization was approximately $48.4 million, and its stockholders’ deficit was about $(4.3) million. The company has been instructed to submit a compliance plan within 45 days, which the NYSE will review to determine if the company can regain compliance within the stipulated timeframe.

Impact

This situation may affect various stakeholders, including investors and employees. Investors may face uncertainty regarding the future trading status of Annovis’ stock, which will continue to be listed under the symbol “ANVS” but will carry a “.BC” designation indicating its non-compliance status. Employees and management must also navigate the potential implications of delisting on the company’s operations and morale.

What’s Next

Annovis Bio has committed to submitting its compliance plan to the NYSE within the specified 45-day period. The outcome of this plan will be crucial in determining whether the company can continue trading on the NYSE or face delisting proceedings.